Heart Failure Clinical Trials
There are 918 actively recruiting heart failure clinical trials across 79 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1, Early Phase 1. Top locations include Dallas, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.
Heart Failure Trials at a Glance
918 actively recruiting trials for heart failure are listed on ClinicalTrialsFinder across 6 cities in 79 countries. The largest study group is Not Applicable with 380 trials, with the heaviest enrollment activity in Dallas, New York, and Boston. Lead sponsors running heart failure studies include Yale University, Mayo Clinic, and University of Texas Southwestern Medical Center.
Browse heart failure trials by phase
Top cities for heart failure trials
Understanding Heart Failure Clinical Trials
Sacubitril/valsartan (Entresto), approved in 2015 after the PARADIGM-HF trial showed it reduced cardiovascular death and heart failure hospitalization by 20% compared to the previous gold standard enalapril, transformed the treatment of heart failure with reduced ejection fraction. Shortly after, the SGLT2 inhibitors dapagliflozin and empagliflozin — originally developed for diabetes — proved in landmark trials (DAPA-HF and EMPEROR-Reduced) to benefit heart failure patients regardless of whether they had diabetes, and subsequently showed benefit in heart failure with preserved ejection fraction as well. These trial-driven advances have expanded the toolkit for heart failure management dramatically in the past decade, and ongoing trials continue to pursue better outcomes for this condition affecting over 60 million people globally.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about Heart Failure clinical trials
Yes. Atrial fibrillation is extremely common in heart failure patients, and most trials allow participants with this co-existing condition. Some trials even focus specifically on patients who have both heart failure and atrial fibrillation. You will need to be on appropriate anticoagulation therapy as determined by your cardiologist.
Yes, and this is a rapidly growing area. After years with few effective treatments for HFpEF, trials have recently demonstrated benefits of SGLT2 inhibitors in this population. New trials are testing additional agents and combination strategies. If you have HFpEF, there are more trial opportunities now than at any previous time.
Most trials require that you be on stable guideline-directed medical therapy (typically including a beta-blocker, an ACE inhibitor or ARB or ARNI, and often an SGLT2 inhibitor) before enrollment. The study drug is usually added to your existing regimen, not substituted for it. Some trials may adjust specific medications as part of the protocol.
Visit frequency varies but is typically every two to four weeks during the first few months and then monthly or bimonthly during the maintenance phase. Visits usually include blood work, vital signs, and symptom assessments. Some trials incorporate remote monitoring that can reduce the number of in-person visits needed.
Heart failure hospitalization is actually a key outcome that most trials track, so the study team is prepared for this scenario. You will continue to receive appropriate inpatient care, and the hospitalization will be documented as a study event. Depending on the circumstances, you may continue in the trial after discharge or be withdrawn per protocol guidelines.
Showing 1–20 of 918 trials